2CHOBANIAN A V,BAKRIS G L,BLACK H R,et al.The Seventh Report of the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure:the JNC 7 report[J].JAMA,2003,289 (19):2560-2572. 被引量：1
3European Society of Hypertension European Society of Cardiology Guidelines Committee.2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension[J].J Hypertens,2003,21(6):1011-1053. 被引量：1
5SEVER P.New hypertension guidelines from the national institute for health and clinical excellence and the British Hypertension Society[J].J Renin Angio tensin Aldosterone Syst,2006,7(2):61-63. 被引量：1
6HANSSON L,ZANCHETTI A,CARRUTHERS S G,et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment(HOT) randomised trial.HOT Study Group[J].Lancet,1998,351(9118):1755-1762. 被引量：1
7ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT)[J].JAMA,2002,288 (23):2981-2997. 被引量：1
8DAHLOF B,DEVEREUX R B,KJELDSEN S E,et al.Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol[J].Lancet,2002,359(9311):995-1003. 被引量：1
9JULIUS S,WEBER M A,KJELDSEN S E,et al.The Valsartan Antihypertensive Long-Term Use Evaluation(VALUE)trial:outcomes in patients receiving monotherapy[J].Hypertension,2006,48(3):385-391. 被引量：1
